Comfortable ophthalmic device and methods of its production

Information

  • Patent Grant
  • 10267952
  • Patent Number
    10,267,952
  • Date Filed
    Tuesday, June 7, 2016
    8 years ago
  • Date Issued
    Tuesday, April 23, 2019
    5 years ago
Abstract
This invention relates to comfortable ophthalmic devices and methods of producing such devices by treating unhydrated, polymerized ophthalmic lens with a polymeric wetting agent, wherein the ophthalmic lens formulation does not comprise said wetting agent prior to its polymerization.
Description
FIELD OF THE INVENTION

This invention relates to comfortable ophthalmic devices and methods of producing such devices.


BACKGROUND

Contact lenses have been used commercially to improve vision since the 1950s. The first contact lenses were made of hard materials. Although these lenses are currently used, they are not suitable for all patients due to their poor initial comfort. Later developments in the field gave rise to soft contact lenses, based upon hydrogels, which are extremely popular today. These lenses have higher oxygen permeabilities and such are often more comfortable to wear than contact lenses made of hard materials. However, these new lenses are not without problems.


Contact lenses can be worn by many users for 8 hours to several days in a row without any adverse reactions such as redness, soreness, mucin buildup and symptoms of contact lens related dry eye. However, some users begin to develop these symptoms after only a few hours of use. Many of those contact lens wearers use rewetting solutions to alleviate discomfort associated with these adverse reactions with some success. However the use of these solutions require that users carry extra solutions and this can be inconvenient. For these users a more comfortable contact lens that does not require the use of rewetting solutions would be useful. Therefore there is a need for such contact lenses and methods of making such contact lenses. It is this need that is met by the following invention.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 Plot of the change in diameter of treated lenses versus control.





DETAILED DESCRIPTION OF THE INVENTION

This invention includes a method of producing ophthalmic lenses comprising, consisting essentially of, or consisting of, treating a polymerized ophthalmic lens with a wetting agent, provided that the ophthalmic lens formulation does not comprise said wetting agent prior to its polymerization.


As used herein, “ophthalmic lens” refers to a device that resides in or on the eye. These devices can provide optical correction or may be cosmetic. Ophthalmic lenses include but are not limited to soft contact lenses, intraocular lenses, overlay lenses, ocular inserts, and optical inserts. The preferred lenses of the invention are soft contact lenses made from silicone elastomers or hydrogels, which include but are not limited to silicone hydrogels, and fluorohydrogels. Soft contact lens formulations are disclosed in U.S. Pat. No. 5,710,302, WO 9421698, EP 406161, JP 2000016905, U.S. Pat. No. 5,998,498, U.S. Pat. No. 6,087,415, U.S. Pat. No. 5,760,100, U.S. Pat. No. 5,776,999, U.S. Pat. No. 5,789,461, U.S. Pat. No. 5,849,811, and U.S. Pat. No. 5,965,631. The foregoing references are hereby incorporated by reference in their entirety. The particularly preferred ophthalmic lenses of the inventions are known by the United States Approved Names of acofilcon A, alofilcon A, alphafilcon A, amifilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A, darfilcon A, deltafilcon A, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, focofilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofilcon B, lotrafilcon A, lotrafilcon B, mafilcon A, mesifilcon A, methafilcon B, mipafilcon A, nelfilcon A, netrafilcon A, ocufilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, ofilcon A, omafilcon A, oxyfilcon A, pentafilcon A, perfilcon A, pevafilcon A, phemfilcon A, polymacon, silafilcon A, siloxyfilcon A, tefilcon A, tetrafilcon A, trifilcon A, and xylofilcon A. More particularly preferred ophthalmic lenses of the invention are genfilcon A, lenefilcon A, comfilcon, lotrafilcon A, lotraifilcon B, and balafilcon A. The most preferred lenses include etafilcon A, nelfilcon A, hilafilcon, and polymacon.


The term “formulation” refers to the un-polymerized mixture of components used to prepare ophthalmic lenses. These components include but are not limited to monomers, pre-polymers, diluents, catalysts, initiators tints, UV blockers, antibacterial agents, polymerization inhibitors, and the like. These formulations can be polymerized, by thermal, chemical, and light initiated curing techniques described in the foregoing references as well as other references in the ophthalmic lens field. As used herein, the terms “polymerized” or “polymerization” refers to these processes. The preferred methods of polymerization are the light initiated techniques disclosed in U.S. Pat. No. 6,822,016 which is hereby incorporated by reference in its entirety.


As used herein the term “treating” refers to physical methods of contacting the wetting agents and the ophthalmic lens. These methods exclude placing a drop of a solution containing wetting agent into the eye of an ophthalmic lens wearer or placing a drop of such a solution onto an ophthalmic lens prior to insertion of that lens into the eye of a user. Preferably treating refers to physical methods of contacting the wetting agents with the ophthalmic lenses prior to selling or otherwise delivering the ophthalmic lenses to a patient. The ophthalmic lenses may be treated with the wetting agent anytime after they are polymerized. It is preferred that the polymerized ophthalmic lenses be treated with wetting agents at temperature of greater than about 50° C. For example in some processes to manufacture contact lenses, an un-polymerized, or partially polymerized formulation is placed between two mold halves, spincasted, or static casted and polymerized. See, U.S. Pat. Nos. 4,495,313; 4,680,336; 4,889,664, 3,408.429; 3,660,545; 4,113,224; and 4,197,266, all of which are incorporated by reference in their entirety. In the case of hydrogels, the ophthalmic lens formulation is a hardened disc that is subjected to a number of different processing steps including treating the polymerized ophthalmic lens with liquids (such as water, inorganic salts, or organic solutions) to swell, or otherwise equilibrate this polymerized ophthalmic lens prior to enclosing the polymerized ophthalmic lens in its final packaging. Polymerized ophthalmic lenses that have not been swelled or otherwise equilibrated are known as un-hydrated polymerized ophthalmic lenses. The addition of the wetting agent to any of the liquids of this “swelling or “equilibrating” step at room temperature or below is considered “treating” the lenses with wetting agents as contemplated by this invention. In addition, the polymerized un-hydrated ophthalmic lenses may be heated above room temperature with the wetting agent during swelling or equilibrating steps. The preferred temperature range is from about 50° C. for about 15 minutes to about sterilization conditions as described below, more preferably from about 50° C. to about 85° C. for about 5 minutes.


Yet another method of treating is physically contacting polymerized ophthalmic lens (either hydrated or un-hydrated) with a wetting agent at between about room temperature and about 85° C. for about 1 minute to about 72 hours, preferably about 24 to about 72 hours, followed by physically contacting the polymerized ophthalmic lens with a wetting agent at between about 85° C. and 150° C. for about 15 minutes to about one hour.


Many ophthalmic lenses are packaged in individual blister packages, and sealed prior to dispensing the lenses to users. As used herein, these polymerized lenses are referred to as “hydrated polymerized ophthalmic lenses”. Examples of blister packages and sterilization techniques are disclosed in the following references which are hereby incorporated by reference in their entirety, U.S. Pat. Nos. D435,966 S; 4,691,820; 5,467,868; 5,704,468; 5,823,327; 6,050,398, 5,696,686; 6,018,931; 5,577,367; and 5,488,815. This portion of the manufacturing process presents another method of treating the ophthalmic lenses with wetting agents, namely adding wetting agents to packaging solution prior to sealing the package, and subsequently sterilizing the package. This is the preferred method of treating ophthalmic lenses with wetting agents.


Sterilization can take place at different temperatures and periods of time. The preferred sterilization conditions range from about 100° C. for about 8 hours to about 150° C. for about 0.5 minute. More preferred sterilization conditions range from about 115° C. for about 2.5 hours to about 130° C. for about 5.0 minutes. The most preferred sterilization conditions are about 124° C. for about 30 minutes.


The “packaging solutions” that are used in methods of this invention may be water-based solutions. Typical packaging solutions include, without limitation, saline solutions, other buffered solutions, and deionized water. The preferred aqueous solution is deioinized water or saline solution containing salts including, without limitation, sodium chloride, sodium borate, sodium phosphate, sodium hydrogenphosphate, sodium dihydrogenphosphate, or the corresponding potassium salts of the same. These ingredients are generally combined to form buffered solutions that include an acid and its conjugate base, so that addition of acids and bases cause only a relatively small change in pH. The buffered solutions may additionally include 2-(N-morpholino)ethanesulfonic acid (MES), sodium hydroxide, 2,2-bis(hydroxymethyl)-2,2′,2″-nitrilotriethanol, n-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid, citric acid, sodium citrate, sodium carbonate, sodium bicarbonate, acetic acid, sodium acetate, ethylenediamine tetraacetic acid and the like and combinations thereof. Preferably, the packaging solution is a borate buffered or phosphate buffered saline solution or deionized water. The particularly preferred packaging solution contains about 1,850 ppm to about 18,500 ppm sodium borate, most particularly preferred about 3,700 ppm of sodium borate.


As used here, the term “wetting agent” refers polymers having a number average molecular weight of about at least 500, that impart a moist feeling when added to the eyes of contact lens wearers. Examples of preferred wetting agents include but are not limited to poly(meth)acrylamides [i.e. poly N,N-dimethylacrylamide), poly (N-methylacrylamide) poly (acrylamide), poly(N-2-hydroxyethylmethacrylamide), and poly(glucosamineacrylamide)], poly(itaconic acid), hyaluronic acid, xanthan gum, gum Arabic (acacia), starch, polymers of hydroxylalkyl(meth)acrylates [i.e. poly(2-hydroxyethylmethacrylate), poly(2,3-dihydroxypropylmethacrylate, and poly(2-hydroxyethylacrylate)], and polyvinylpyrrolidone.


Additional preferred wetting agents include but are not limited to co-polymers and graft co-polymers of the aforementioned preferred wetting agents, such co-polymers and graft co-polymers include repeating units of hydrophilic or hydrophobic monomers, preferably in amounts of about less than ten percent by weight, more preferably less than about two percent. Such repeating units of hydrophilic or hydrophobic monomers include but are not limited to alkenes, styrenes, cyclic N-vinyl amides, acrylamides, hydroxyalkyl (meth) acrylates, alkyl (meth) acrylates, siloxane substituted acrylates, and siloxane substituted methacrylates. Specific examples of hydrophilic or hydrophobic monomers which may be used to form the above co-polymers and graft co-polymers include but are not limited to ethylene, styrene, N-vinylpyrrolidone, N,N-dimethylacrylamide, 2-hydroxyethylmethyacrylate, methyl methacrylate and butyl methacrylate, methacryloxypropyl tristrimethylsiloxysilane and the like. The preferred repeating units of hydrophilic or hydrophobic monomers are N-vinylpyrrolidone, N,N-dimethylacrylamide, 2-hydroxyethylmethacrylate, methyl methacrylate, and mixtures thereof. Further examples of wetting agents include but are not limited to polymers with carbon backbones and pendant polyethylene glycol chains [i.e. polymers of polyethylene glycol monoomethacrylate] copolymers of ethylene glycol [copolymers with 1,2,propyleneglycol, 1,3-propylene glycol, methyleneglycol, and tetramethylene glycol]. The preferred wetting agents are polyvinylpyrrolidone, graft co-polymers and co-polymers of polyvinylpyrrolidone, the particularly preferred wetting agent is polyvinylpyrrolidone. Polyvinylpyrrolidone (“PVP”) is the polymerization product of N-vinylpyrrolidone. PVP is available in a variety of molecular weights from about 500 to about 6,000,000 Daltons. These molecular weights can be expressed in term of K-values, based on kinematic viscosity measurements as described in Encyclopedia of Polymer Science and Engineering, John Wiley & Sons Inc, and will be expressed in these numbers throughout this application. The use of PVP having the following K-values from about K-30 to about K-120 is contemplated by this invention. The more preferred K-values are about K-60 to about K-100, most preferably about K-80 to about K-100. For the treatment of etafilcon A lenses, the particularly preferred K-value of PVP is about K-80 to about K-95, more preferably about K-85 to about K-95, most preferably about K-90.


The wetting agents can be added to the packaging solution at a variety of different concentrations such as about 100 ppm to about 150,000 ppm. For example if the wetting agents are added to packaging solutions containing un-hydrated polymerized ophthalmic lenses, the wetting agents are preferably present at a concentration of about 30,000 ppm to about 150,000 ppm. If the wetting agents are added to packaging solutions containing hydrated polymerized ophthalmic lenses, the wetting agents are preferably present at a concentration of about 100 ppm, to about 3000 ppm, more preferably about 200 ppm to about 1000 ppm, most preferably less than about 500 ppm. For example when etafilcon A lenses are used in this invention and the wetting agent is K-90 PVP, the preferred packaging solution concentration of PVP K-90 is about 250 ppm to about 2,500 ppm, more preferably about 300 to about 500 ppm, most preferably about 350 to about 440 ppm.


When etafilcon A contact lenses are heated with K-90 PVP at a temperature greater than about 120° C. for about 30 minutes at a concentration of about 400 to about 500 ppm, the treated lenses are more comfortable to users than untreated lenses. Further, this particular molecular weight and concentration of PVP does not distort or shift the diameter of the lenses during the treatment cycle or distort the users vision. While not wishing to be bound by any particular mechanism of incorporation, it is known that K-90 PVP is incorporated into the matrix of the lens after it is treated with K-90 PVP. In an etafilcon A contact lens, the preferred amount of incorporated K-90 PVP is about 0.01 mg to about 1.0 mg, more preferred about 0.10 mg to about 0.30 mg, most particularly preferred about 0.10 mg to about 0.20 mg. Lenses that have been treated in this manner are worn by users for up to 12 hours still maintain the incorporated PVP.


Further the invention includes an ocular device comprising, consisting essentially of, or consisting of a polymerized ophthalmic lens wherein said polymerized ophthalmic lens is treated with a wetting agent, provided that the ophthalmic lens formulation does not comprise said wetting agent prior to its polymerization. The terms “ophthalmic lens,” “wetting agent,” “polymerized,” and “formulation” all have their aforementioned meanings and preferred ranges. The term “treated” has the equivalent meaning and preferred ranges as the term treating.


Still further the invention includes an ocular device prepared by treating a polymerized ophthalmic lens with a wetting agent, provided that the ophthalmic lens formulation does not comprise said wetting agent prior to its polymerization. The terms “ophthalmic lens,” “wetting agent,” “polymerized,” “treated” and “formulation” all have their aforementioned meanings and preferred ranges.


The application of the invention is described in further detail by use of the following examples. These examples are not meant to limit the invention, only to illustrate its use. Other modifications that are considered to be within the scope of the invention, and will be apparent to those of the appropriate skill level in view of the foregoing text and following examples.


EXAMPLES
Example 1

Cured etafilcon A contact lenses (sold as 1-Day Acuvue® brand contact lenses by Johnson & Johnson Vision Care, Inc.) were equilibrated in deionized water, and packaged in solutions containing PVP in borate buffered saline solution ((1000 mL, sodium chloride 3.55 g, sodium borate 1.85 g, boric acid 9.26 g, and ethylenediamine tetraacetic acid 0.1 g: 5 rinses over 24 hours, 950±μL), sealed with a foil lid stock, and sterilized (121° C., 30 minutes). Before the addition of PVP each solution contained water, 1000 mL, sodium chloride 3.55 g, sodium borate 1.85 g, boric acid, 9.26 g, and ethylenediamine tetraacetic acid 0.1 g. A variety of different weights and concentrations of PVP were used as shown in Table 1, below.


The amount of PVP that is incorporated into each lens is determined by removing the lenses from the packaging solution and extracting them with a mixture 1:1 mixture of N,N-dimethylforamide, (DMF) and deionized water (DI). The extracts are evaluated by high performance liquid chromatography (HPLC). Three lenses were used for each evaluation. The results and their standard deviation are presented in Table 1.












TABLE 1








mg of PVP


Sample #
Type of PVP
Conc. (ppm)
in lens







Control
None
None
none


1
K-12
3000
0.24 (0.01)


2
K-12
20,000
1.02 (0.01)


3
K-30
1500
1.39 (0.05)


4
K-30
2000
1.50 (0.01)


5
K-60
1000
0.56 (0.00)


6
K-60
1500
0.85 (0.02)


7
K-60
2500
1.02 (0.03)


8
K-90
250
0.10 (0.00)


9
K-90
500
0.14 (0.00)


10
K-90
1000
 0.2 (0.01)


11
K-90
2500
0.25 (0.02)


12
K-120
500
0.07 (0.00)









Example 2

Samples of treated etafilcon A lenses were prepared via the treatment and sterilization methods of Example 1 from K-12, K-30, K-60, K-90, and K-120 PVP at concentrations of 0.30%, 1.65%, and 3.00%. After sterilization, the diameter of the lenses was, compared to an untreated lens and evaluated to determine if the process changed those diameters. The results, FIG. 1, plot the change in diameter vs the type of PVP at a particular concentration. This data shows that K-12, K-90, and K-120 have a minimal effect on the diameter of the lenses.


Example 3

Several etafilcon A lenses were treated with K-90 PVP at a concentration of 500 ppm and sterilized according to the methods of Example 1. The lenses were stored in their packages for approximately 28 days at room temperature and were then measured for diameter, base curve, sphere power, and center thickness. Thereafter, lenses were heated at 55° C. for one month. The diameter, base curve, sphere power, and center thickness of the lenses was measured and the results were evaluated against an untreated lens and data is presented in Table 2. This data illustrates that the parameters of lenses treated with K-90 PVP are not significantly affected by time at elevated temperature.












TABLE 2








Change from




Baseline of




Sample after one




month storage at



Baseline
55° C.




















Diameter (mm)
14.37 (0.02) 
0.02



Base curve (mm)
8.90 (0.03)
−0.01



Power (diopter)
−0.75 (0.05) 
0.00



Center Thickness
0.127 (0.005)
0.002



(mm)










Example 4

Etafilcon-A lenses treated with PVP K-90 at a concentration of 440 ppm and sterilized (124° C., approximately 18 minutes) were sampled from manufacturing lines and measured for diameter, base curve, sphere power, and center thickness and compared to similar measurements made on untreated 1-Day Acuvue® brand lenses. The data presented in Table 3 illustrates that K-90 PVP does not significantly affect these parameters.












TABLE 3







Treated
Untreated




















Diameter (mm)
14.24 (0.04) 
14.18 (0.04) 



Base curve (mm)
8.94 (0.03)
8.94 (0.04)



Sphere Power Deviation
−0.01 (0.04) 
−0.02 (0.04) 



from Target (diopter)



Center Thickness Deviation
0.000 (0.004)
0.002 (0.005)



from Target (mm)










Example 5

Etafilcon A lenses were prepared according to Example 1 at the concentrations of Table 1. The treated lenses were clinically evaluated in a double-masked studies of between 9 and 50 patients. The patients wore the lenses in both eyes for 3-4 days with overnight removal and daily replacement, and wore untreated 1-Day Acuvue® brand contact lenses for 3-4 days with overnight removal and daily replacement as a control. Patients were not allowed to use rewetting drops with either type of lens. Patients were asked to rate the lens using a questionnaire. All patients were asked a series of questions relating to overall preference, comfort preference, end of day preference, and dryness. In their answers they were asked to distinguish if they preferred the treated lens, the 1-Day control lens, both lenses or neither lens. The results are shown in Tables 4 and 5. The numbers in the columns represent the percentage of patients that positively responded to each of the four options. The “n” number represents the number of patients for a particular sample type. “DNT” means did not test and n/a means non applicable. The numbers illustrate that lenses treated with K-90 PVP at a concentration of about 500 ppm have good clinical comfort on the eye. The sample # refers to the sample numbers in Table 1.












TABLE 4









Overall Preference, %
Comfort Preference, %


















PVP



PVP





Sample #
n
treated
1-Day
Both
Neither
treated
1-Day
Both
Neither



















1
9
67
22
11
0
67
22
11
0


2
37
27
49
22
3
30
46
19
5


3
41
34
49
15
2
27
56
12
5


4
10
30
20
50
0
30
40
30
0


5
41
27
61
10
2
22
49
29
0


6
42
33
33
33
0
33
29
38
0


7
37
51
27
19
3
49
11
38
3


8
41
27
37
32
5
24
34
37
5


9
48
33
27
40
0
33
23
44
0


10
45
18
27
51
4
16
20
58
7



















TABLE 5









Dryness Preference %
End of Day Preference %


















PVP



PVP





Sample #
n
treated
1-Day
Both
Neither
treated
1-Day
Both
Neither



















1
9
33
33
11
0
56
22
44
0


2
37
24
43
22
8
27
43
27
5


3
41
32
51
17
2
29
49
17
2


4
10
20
40
30
10
20
10
60
10


5
41
20
46
32
2
20
41
37
2


6
31
42
24
38
0
38
35
16
6


7
42
36
19
38
3
41
24
40
0


8
41
27
22
49
7
22
24
41
7


9
48
38
21
46
0
33
19
44
0


10
45
24
20
58
4
18
20
51
4









Example 6

An etafilcon A contact lens was treated with 500 ppm of K-90 PVP using the methods of Example 1. The treated lenses were briefly rinsed with phosphate buffered saline solution and rinsed lenses were placed in the well of a cell culture cluster container (Cellgrow XL) that mimics the dimensions of a human eye. See, Farris R L, Tear Analysis in Contact Lens Wears, Tr. Am. Opth. Soc. Vol. LXXXIII, 1985. Four hundred microliters of phosphate buffered saline solution (KH2PO4 0.20 g/L, KCl 0.20 g/L, NaCl 8.0 g/L, Na2HPO4 [anhydrous] 1.15 g/L) was added to each container. The wells were covered and the container was stored in an oven at 35° C.


Three lenses were removed from the oven at various times and analyzed by HPLC to determine whether PVP was released into the phosphate buffered saline solution. The average results are presented in Table 6. The limit of quantification for PVP is 20 ppm. The test did not detect any PVP in the analyzed samples. This data shows that PVP is not released at levels greater than 20 ppm.












TABLE 6







Time
PVP Released









30 min.
<20 ppm



 1 hr.
<20 ppm



 2 hr.
<20 ppm



 4 hr.
<20 ppm



 8 hr.
<20 ppm



16 hr.
<20 ppm



24 hr
<20 ppm









Claims
  • 1. A method of producing ophthalmic lenses comprising, treating an unhydrated, polymerized ophthalmic lens formed by polymerizing an ophthalmic lens formulation (a) with a solution comprising about 200 to about 1000 ppm of at least one wetting agent selected from the group consisting of polyvinylpyrrolidone, graft co-polymers of polyvinylpyrrolidone, and co-polymers of polyvinylpyrrolidone each having a K value between about K-60 to about K-120; and (b) heating said polymerized ophthalmic lens and solution to a temperature of at least about 50° C. to about 150° C., wherein the ophthalmic lens formulation does not comprise said wetting agent prior to its polymerization.
  • 2. The method of claim 1 wherein the K-value of the polyvinylpyrrolidone is about K-85 to about K-95.
  • 3. The method of claim 1 wherein the K-value of polyvinylpyrrolidone is about K-90.
  • 4. The method of claim 1 wherein treating comprises heating the polymerized ophthalmic lens in a packaging solution comprising polyvinylpyrrolidone having a K-value of about K-85 to about K-95 at a temperature of greater than about 80° C.
  • 5. The method of claim 1 wherein treating comprises heating the polymerized ophthalmic lens in a packaging solution comprising polyvinylpyrrolidone having a K-value of about K-85 to about K-95 at a temperature of greater than about 120° C.
  • 6. The method of claim 1 wherein the polymerized ophthalmic lens is heated at about 124° C. for about 18 minutes and with polyvinylpyrrolidone having a K-value of about K-90 at a concentration of about 400 to about 440 ppm.
  • 7. The method of claim 1 wherein the polymerized ophthalmic lens is heated at about 121° C. for about 30 minutes and with polyvinylpyrrolidone having a K-value of about K-90 at a concentration of about 300 to about 400 ppm.
  • 8. The method of claim 6 wherein the treating step is conducted in an individual sealed contact lens package.
  • 9. The method of claim 1 wherein the ophthalmic lens is selected from the group consisting of acofilcon A, alofilcon A, alphafilcon A, amifilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A, darfilcon A, deltafilcon A, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, focofilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofilcon B, lotrafilcon A, lotrafilcon B, mafilcon A, mesifilcon A, methafilcon B, mipafilcon A, nelfilcon A, netrafilcon A, ocufilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, ofilcon A, omafilcon A, oxyfilcon A, pentafilcon A, perfilcon A, pevafilcon A, phemfilcon A, polymacon, silafilcon A, siloxyfilcon A, tefilcon A, tetrafilcon A, trifilcon A, and xylofilcon A.
  • 10. The method of claim 4 wherein the ophthalmic lens is selected from the group consisting of acofilcon A, alofilcon A, alphafilcon A, amifilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A, darfilcon A, deltafilcon A, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, focofilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofilcon B, lotrafilcon A, lotrafilcon B, mafilcon A, mesifilcon A, methafilcon B, mipafilcon A, nelfilcon A, netrafilcon A, ocufilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, ofilcon A, omafilcon A, oxyfilcon A, pentafilcon A, perfilcon A, pevafilcon A, phemfilcon A, polymacon, silafilcon A, siloxyfilcon A, tefilcon A, tetrafilcon A, trifilcon A, and xylofilcon A.
  • 11. The method of claim 4 wherein the ophthalmic lens is selected from the group consisting of genfilcon A, lenefilcon A, lotrafilcon A, lotrafilcon B, balafilcon A, comfilcon, etafilcon A, nelfilcon A, hilafilcon, and polymacon.
  • 12. The method of claim 4 wherein the ophthalmic lens is selected from the group consisting of etafilcon A, nelfilcon A, hilafilcon, and polymacon.
  • 13. The method of claim 4 wherein the ophthalmic lens is selected from the group consisting of etafilcon A.
  • 14. The method of claim 6 wherein the ophthalmic lens is an etafilcon A contact lens.
  • 15. The method of claim 1 wherein the treating comprises contacting the unhydrated polymerized ophthalmic lens with a packaging solution comprises about 1870 ppm to about 18,700 ppm sodium borate.
  • 16. The method of claim 1 wherein the treating further comprises heating the unhydrated polymerized ophthalmic lens in a packaging solution to a temperature of at least about 50° C. to about 100° C.
  • 17. The method of claim 1 wherein the treating further comprises maintaining the unhydrated polymerized ophthalmic lens and packaging solution at a temperature of at least about 10° C. to about room temperature.
  • 18. The method of claim 15 wherein the packaging solution further comprises deionized water or saline solution.
  • 19. The method of claim 1 wherein the K-value of the polyvinylpyrrolidone is about K-60 to about K-90.
  • 20. The method of claim 15 further comprising an additional step of heating the unhydrated polymerized ophthalmic lens with an additional portion of packaging solution comprising an additional wetting agent.
  • 21. The method of claim 20 wherein the at least one wetting agent is polyvinylpyrrolidone having a K-value of about K-60 and the additional wetting agent is polyvinylpyrrolidone having a K-value of about K-90.
  • 22. The method of claim 20 wherein the at least one wetting agent is polyvinylpyrrolidone having a K-value of about K-90 and the additional wetting agent is polyvinylpyrrolidone having a K-value of about K-90.
RELATED APPLICATIONS

This application is a divisional of U.S. Ser. No. 14/196,006, filed Mar. 4, 2014, now U.S. Pat. No. 9,395,559, issued Jul. 19, 2016, which is a divisional of U.S. Ser. No. 12/896,930, filed Oct. 4, 2010, now U.S. Pat. No. 8,696,115, issued Apr. 15, 2014, which is a continuation of U.S. Ser. No. 11/351,907, filed Feb. 10, 2006, now U.S. Pat. No. 7,841,716 issued Nov. 30, 2010, which is a non-provisional filing of two provisional applications, U.S. Ser. No. 60/652,809, filed on Feb. 14, 2005 and U.S. Ser. No. 60/695,783 filed on Jun. 30, 2005.

US Referenced Citations (207)
Number Name Date Kind
2847407 Hosmer Aug 1958 A
3311577 Rankin Mar 1967 A
3408429 Wichterle Oct 1968 A
3621079 Leeds Nov 1971 A
3660545 Wichterle May 1972 A
3700761 O'Driscoll et al. Oct 1972 A
3721657 Seiderman Mar 1973 A
3767731 Seiderman Oct 1973 A
3767788 Rankin Oct 1973 A
3808178 Gaylord Apr 1974 A
3841598 Grucza Oct 1974 A
3841985 O'Driscoll et al. Oct 1974 A
3888782 Boghosian et al. Jun 1975 A
3894129 Hoffman et al. Jul 1975 A
3910761 Hopkins Oct 1975 A
3947573 Rankin Mar 1976 A
3959102 Wajs et al. May 1976 A
3966847 Seiderman Jun 1976 A
3978164 Le Boeuf et al. Aug 1976 A
4018853 Le Boeuf et al. Apr 1977 A
RE29231 Leeds May 1977 E
4029817 Blanco et al. Jun 1977 A
4038264 Rostoker et al. Jul 1977 A
4042552 Grucza Aug 1977 A
4045547 Le Boeuf et al. Aug 1977 A
4054624 Le Boeuf et al. Oct 1977 A
4062627 Wajs et al. Dec 1977 A
4113224 Clark et al. Sep 1978 A
4120570 Gaylord Oct 1978 A
4123408 Gordon Oct 1978 A
4136250 Mueller et al. Jan 1979 A
4153641 Deichert et al. May 1979 A
4157892 Tanaka et al. Jun 1979 A
4190277 England Feb 1980 A
4197266 Clark et al. Apr 1980 A
4321261 Ellis et al. Mar 1982 A
4407791 Stark Oct 1983 A
4451629 Tanaka et al. May 1984 A
4460573 Huth et al. Jul 1984 A
4495313 Larsen Jan 1985 A
4525346 Stark Jun 1985 A
4529535 Sherman Jul 1985 A
4560491 Sherman Dec 1985 A
4615882 Stockel Oct 1986 A
4626292 Sherman Dec 1986 A
4670178 Huth et al. Jun 1987 A
4680336 Larsen et al. Jul 1987 A
4691820 Martinez Sep 1987 A
4729914 Kliment et al. Mar 1988 A
4731192 Kenjo et al. Mar 1988 A
4740533 Su et al. Apr 1988 A
4866148 Geyer et al. Sep 1989 A
4889664 Kindt-Larsen et al. Dec 1989 A
4910277 Bambury et al. Mar 1990 A
4961954 Goldberg et al. Oct 1990 A
4976969 Plamondon Dec 1990 A
5001009 Whitbourne Mar 1991 A
5006622 Kunzler et al. Apr 1991 A
5034461 Lai et al. Jul 1991 A
5039459 Kindt-Larsen et al. Aug 1991 A
5057578 Spinelli Oct 1991 A
5070170 Robertson et al. Dec 1991 A
5070215 Bambury et al. Dec 1991 A
5094876 Goldberg et al. Mar 1992 A
5100689 Goldberg et al. Mar 1992 A
5117165 Cassat et al. May 1992 A
5130124 Merianos et al. Jul 1992 A
5135297 Valint, Jr. Aug 1992 A
5141665 Sherman Aug 1992 A
5244981 Seidner et al. Sep 1993 A
5256751 Vanderlaan Oct 1993 A
5300296 Holly et al. Apr 1994 A
5311223 Vanderlaan May 1994 A
5312588 Gyulai et al. May 1994 A
5314960 Spinelli et al. May 1994 A
5314961 Anton et al. May 1994 A
5321108 Kunzler et al. Jun 1994 A
5322667 Sherman Jun 1994 A
5331067 Seidner et al. Jul 1994 A
5338480 Dziabo et al. Aug 1994 A
5338814 Wu et al. Aug 1994 A
5356555 Huth et al. Oct 1994 A
5362815 Shih et al. Nov 1994 A
5364918 Valint, Jr. et al. Nov 1994 A
5373074 Wu et al. Dec 1994 A
5380303 Holly et al. Jan 1995 A
5387662 Kunzler et al. Feb 1995 A
5436068 Kobayashi et al. Jul 1995 A
5443801 Langford Aug 1995 A
5451303 Heiler et al. Sep 1995 A
5466853 Koinuma et al. Nov 1995 A
5467868 Abrams et al. Nov 1995 A
5496871 Lai et al. Jan 1996 A
5488815 Abrams et al. Feb 1996 A
5525691 Valint, Jr. et al. Jun 1996 A
5539016 Kunzler et al. Jul 1996 A
5577367 Abrams et al. Nov 1996 A
5603897 Heiler et al. Feb 1997 A
5641450 Kobayashi et al. Jun 1997 A
5652638 Roffman et al. Jul 1997 A
5696686 Sanka et al. Dec 1997 A
5704468 Lust et al. Jan 1998 A
5710302 Kunzler et al. Jan 1998 A
5726733 Lai et al. Mar 1998 A
5760100 Nicolson et al. Jun 1998 A
5773396 Zhang et al. Jun 1998 A
5776999 Nicolson et al. Jul 1998 A
5782992 Frangione Jul 1998 A
5789461 Nicolson et al. Aug 1998 A
5800807 Hu et al. Sep 1998 A
5805260 Roffman et al. Sep 1998 A
5807944 Hirt et al. Sep 1998 A
5823327 Wu et al. Oct 1998 A
5840671 Fujimura et al. Nov 1998 A
5849811 Nicolson et al. Dec 1998 A
5885566 Goldberg Mar 1999 A
5902606 Wunderlich et al. May 1999 A
5942589 Wunsch et al. Aug 1999 A
5944853 Molock et al. Aug 1999 A
5965631 Nicolson et al. Oct 1999 A
5998498 Vanderlaan et al. Dec 1999 A
6018931 Byram et al. Feb 2000 A
6039913 Hirt et al. Mar 2000 A
6050398 Wilde et al. Apr 2000 A
6087415 Vanderlaan et al. Jul 2000 A
6093686 Nakada et al. Jul 2000 A
6126706 Matsumoto et al. Oct 2000 A
6162393 De Bruiju et al. Dec 2000 A
D435966 Duis et al. Jan 2001 S
6180093 De et al. Jan 2001 B1
6183082 Clutterbuck Feb 2001 B1
6190651 Nakada et al. Feb 2001 B1
6258591 Yoneda et al. Jul 2001 B1
6274133 Hu et al. Aug 2001 B1
6338847 Thomas Jan 2002 B1
6367929 Maiden et al. Apr 2002 B1
6372815 Sulc et al. Apr 2002 B1
6406739 LeBoeuf et al. Jun 2002 B1
6428353 Mochizuki Aug 2002 B2
6440366 Salpekar et al. Aug 2002 B1
6444776 Holland et al. Sep 2002 B1
6488965 Karageozian Dec 2002 B1
6511949 Nitta et al. Jan 2003 B1
6528048 Koike et al. Mar 2003 B1
6565776 Li et al. May 2003 B1
6617373 Sul et al. Sep 2003 B2
6699435 Saipekar et al. Mar 2004 B2
6733123 Polzhofer et al. May 2004 B2
6815074 Aguado et al. Nov 2004 B2
6822016 McCabe et al. Nov 2004 B2
6849671 Steffen et al. Feb 2005 B2
6861123 Turner et al. Mar 2005 B2
6867172 Alvarez et al. Mar 2005 B2
6940580 Winterton et al. Sep 2005 B2
6992118 Sulc et al. Jan 2006 B2
7052131 McCabe et al. May 2006 B2
7143990 Matsuzawa et al. Dec 2006 B2
7147844 Hamano et al. Dec 2006 B2
7262232 Sulc et al. Aug 2007 B2
7431152 Marmo Oct 2008 B2
7435452 Shimoyama et al. Oct 2008 B2
7841716 McCabe et al. Nov 2010 B2
8672475 Liu et al. Mar 2014 B2
8696115 McCabe et al. Apr 2014 B2
9052529 McCabe Jun 2015 B2
20010036556 Jen Nov 2001 A1
20010044482 Hu et al. Nov 2001 A1
20020039984 Ketelson et al. Apr 2002 A1
20020058601 Jordan, IV et al. May 2002 A1
20030044447 Zanini et al. Mar 2003 A1
20030109390 Salpekar Jun 2003 A1
20030162862 McCabe et al. Aug 2003 A1
20030164562 Li et al. Sep 2003 A1
20030191043 Becker et al. Oct 2003 A1
20040091613 Wood et al. May 2004 A1
20040097504 Bethiel et al. May 2004 A1
20040114105 Shimoyama et al. Jun 2004 A1
20040120982 Diana et al. Jun 2004 A1
20040130676 Doshi et al. Jul 2004 A1
20040137079 Cook et al. Jul 2004 A1
20040142829 Tsao et al. Jul 2004 A1
20040150788 Andersson et al. Aug 2004 A1
20040186028 Hu et al. Sep 2004 A1
20040192872 Iwata et al. Sep 2004 A1
20040214914 Marmo Oct 2004 A1
20050059639 Wei Mar 2005 A1
20050074467 Fujita et al. Apr 2005 A1
20050117112 Nayiby et al. Jun 2005 A1
20050154080 McCabe et al. Jul 2005 A1
20050179862 Steffen et al. Aug 2005 A1
20070010595 McCabe et al. Jan 2007 A1
20070043140 Lorenz et al. Feb 2007 A1
20070119721 Marmo May 2007 A1
20070229758 Matsuzawa Oct 2007 A1
20080045612 Rathore et al. Feb 2008 A1
20080100796 Pruitt et al. May 2008 A1
20080141628 Lang et al. Jun 2008 A1
20080148689 Xia et al. Jun 2008 A1
20080299179 Rathore et al. Dec 2008 A1
20090059165 Pruitt et al. Mar 2009 A1
20090182067 Liu Jul 2009 A1
20100162663 McGee et al. Jul 2010 A1
20100238399 Rathore Sep 2010 A1
20110262519 Franklin et al. Oct 2011 A1
20120026457 Qiu et al. Feb 2012 A1
20130293831 Norris et al. Nov 2013 A1
20140016086 Liu et al. Jan 2014 A1
Foreign Referenced Citations (76)
Number Date Country
1074450 Jul 1993 CN
1230882 Oct 1999 CN
0080539 Jun 1983 EP
349487 Jan 1990 EP
358447 Mar 1990 EP
472496 Feb 1992 EP
487994 Jun 1992 EP
406161 Feb 1995 EP
482836 Mar 1995 EP
482837 Mar 1995 EP
486653 May 1996 EP
600828 Mar 1997 EP
437179 Apr 1998 EP
456467 Apr 1998 EP
836111 Apr 1998 EP
580662 Jun 1998 EP
577143 Jan 1999 EP
650354 Dec 1999 EP
979659 Feb 2005 EP
1327893 Jul 2006 EP
1212758 Nov 1970 GB
58216222 Dec 1983 JP
199086643 Mar 1990 JP
4370197 Dec 1992 JP
1993173098 Jul 1993 JP
1994312013 Nov 1994 JP
8500382 Jan 1996 JP
1996196270 Aug 1996 JP
10114807 May 1998 JP
1998221654 Aug 1998 JP
2899347 Jun 1999 JP
2000016905 Jan 2000 JP
2000056277 Feb 2000 JP
2000239696 Sep 2000 JP
2000347145 Dec 2000 JP
2000347146 Dec 2000 JP
2001508555 Jun 2001 JP
2001247466 Sep 2001 JP
2002025690 Jan 2002 JP
2002243190 Aug 2002 JP
3343443 Nov 2002 JP
2003248200 Sep 2003 JP
2003311762 Nov 2003 JP
2004085655 Mar 2004 JP
2004537348 Dec 2004 JP
2005513173 May 2005 JP
19900008008 Oct 1990 KR
567215 Dec 2003 TW
592738 Jun 2004 TW
9309154 May 1993 WO
1994004028 Mar 1994 WO
1994009794 May 1994 WO
1994015648 Jul 1994 WO
1994016743 Aug 1994 WO
1994021698 Sep 1994 WO
1995020969 Aug 1995 WO
9631792 Oct 1996 WO
1997049740 Dec 1997 WO
1998011875 Mar 1998 WO
1998030248 Jul 1998 WO
2000002937 Jan 2000 WO
2000019981 Apr 2000 WO
2000037048 Jun 2000 WO
2000037541 Jun 2000 WO
2000059970 Oct 2000 WO
2001009211 Feb 2001 WO
2001071392 Sep 2001 WO
2001082984 Nov 2001 WO
2002092143 Nov 2002 WO
2003022321 Mar 2003 WO
2003022322 Mar 2003 WO
2003057270 Jul 2003 WO
2004010204 Jan 2004 WO
2004028536 Apr 2004 WO
2006012000 Feb 2006 WO
2006088758 Aug 2006 WO
Non-Patent Literature Citations (33)
Entry
Aquavella et al, Therapeutic Effects of Bionite Lenses: Mechanisms of Action, Annals of Ophthalmology (12):1341-1345, 1971, 10 pages.
Barabas, (1989) “N-Vinyl Amide Polymers”, Encyclopedia of Polymer Science and Engineering, 2nd Edition, vol. 17, 198-257, John Wiley & Sons, Inc, New York, 63 pages.
Brewitt et al, Rewetting of contact lenses: Clinical data on efficacy and necessity, Contactologia, International Medical Contact Lens Journal, German Edition, vol. 16, No. 3, 3rd Quarter 1994 (III), pp. 87-142, 10 pages.
Chalyovska et al, Development of a Medium for Improving the Tolerance of Contact Lenses, Their Maintenance and Storage, Annals of Sofia University named after Kliment Ohridski College of Chemistry, vol. 74, 1984 Translation, 4 pages.
Comelli et al, Estimation of Molecular Weight Distribution of Poly(Vinylpyrrolidone) from Diaphragm-Cell Diffusion Measurements, Polymer Engineering & Science, vol. 20, No. 5, Mar. 1980, 6 pages.
Crivello, et al, Photoinitiators for Free Radical Cationic & Anionic Photopolymerisation, 2nd Edition, vol. III, pp. 275-298, John Wiley and Sons, New York, 1998.
Das et al, Evaluation of Glutaraldehyde and Povidone Iodine for Sterilization of Wide-Field Contact Vitrectomy Lenses, Ophthalmic Surgery and Lasers, vol. 32, No. 4, pp. 300-304, Jul./Aug. 2001.
Das et al, Rapid Sterilization of Wide Field Contact Lens Used in Vitreo-Retinal Surgery, Investigative Ophthalmology & Visual Science vol. 40, No. 4, Mar. 15, 1999, 1 page.
De La Iglesia et al, Soft Contact Lens Studies in Rabbit Eyes, Toxicology and Applied Pharmacology 29(1):96-97, 1974, 1 page.
Dexter, Interactions of Anionic Surfactants and Polymers Used as Spray Tank Adjuvants, 16th Volume, ASTM STP (1312):77-92, 1996.
Dimitrova et al, Formulation of New Products—Purolens and Filmolens, for Maintenance of Hard Contact Lenses, Formats, XXXIII, vol. 5, 1983, 5 pages.
Federov et al, A Liquid-Chromatographic Study of the Molecular Mass and Composition Heterogeneity of Random Copolymers of N-Vinyipyrrolidone and 2-Methyl-5-vinylpyridine, Polymer Science Series A, vol. 36,No. 9, pp. 11291-1294, 1994.
Fleig et al, The Effect of Column Geometry on Separation Effectiveness of Agarose for Poly(Vinyl Pyrrolidone), Chemical Engineering Communications, vol. 13, pp. 219-229, 1982.
Hoefle, Contact Lens Materials: Past, Present, and Future, American Academy of Ophthalmology and Otolaryngology, vol. 78, No. 3, pp. OP386-390, May/Jun. 1974.
Hornbrook et al, Soft Flexible Contact Lenses, The Medical Journal of Australia, pp. 649-653, Sep. 29, 1973.
ISO 9913-1: 1996: Optics and optical instruments—Contact Lenses—Part 1: Determination of oxygen permeability and transmissibility by the FATT method, 16 pages.
Jiang et al, Characterization of water-soluble polymers by flow FFF-MALS, American Laboratory, pp. 98-108, Feb. 2000, 11 pages.
Kunzler, “Silicone Hydrogels for Contact Lens Application”, Trends in Polymer Science, Feb. 1996, pp. 52-59, vol. 4, No. 2, Elsevier Trends Journals, Cambridge, UK.
Leonard-Stibbe et al, The Cationic Polymerisation of N-Vinyl-2-pyrrolidone Initiated Electrochemically by Anodic Polarisation on a Pt Surface, Journal of Polymer Science: Part A: Polymer Chemistry, vol. 32, pp. 1551-1555, (1994), 5 pages.
Manning, The Application of Centrifugation to Polymer Fractionation, Dissertation Abstracts International. Section B, The Sciences and Engineering 32(9):5164-5, 1972, 3 pages.
McCarey et al, Refractive keratoplasty with intrastromal hydrogel lenticular implants, Investigative Ophthalmology & Visual Science 21(1 Part 1):107-115, Jul. 1981.
PCT International Preliminary Report on Patentability dated Aug. 14, 2007, or PCT Int'l. Appln. No. PCT/US2006/004877, 8 pages.
PCT International Search Report dated Jul. 15, 2011 PCT Int'l Appln No. PCT/US2011/032413, 5 pages.
PCT International Search Report, dated Feb. 9, 2007, for PCT Int'l. Appln. No. PCT/US2006/004877, 4 pages.
Pilyugina et al, In Vitro Epithelialization of a Synthetic Polymer for Generation of Corneal Onlay/keratoprosthesis, Investigative Ophthalmology & Visual Science 44: E-Abstract, pp. 1344-B240, May 2003, 2 pages.
Princz et al., Release of Wetting Agents from Nelfilcon Contact Lenses, investigative Ophthalmology & Visual Science, Association for Research in Vision, vol. 46, No. Suppl S, May 2005, p. 907-B881, 1 page.
Refojo, Contact Lenses and Pharmaceutical Solutions for Their Care, Storage and Disinfection, Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, MA, An. Real Acad, Farm., 1996, 62: 401-420.
Riedhammer et al, Effects of long-term heat disinfection on Softens (polymacon) contact lenses, Journal of the American Optometric Association, vol. 51; No. 3, pp. 287-289, Mar. 1980.
Riedhammer, Colorimetric Determination of Poly(N-Vinyl-2-Pyrrolidone) in Contact Lens Solutions, Journal of the Association of Official Analytical Chemists, vol. 62, No. 1, 52-55, 1979.
Rucker et al, A Safety Test for Contact Lens Wetting Solutions, Annals of Ophthalmology, pp. 1000-1006; Nov. 1972.
Special 510 (k) Summary of Safety and Efficacy for VISTAKON®, dated Nov. 1, 2006, 9 pages.
Udupa et al, Studies on Physicochemical Properties of Viscosity Building Agents Used in Contact Lens Solutions, The Indian Journal Hospital Pharmacy, vol. 13, 184-189, Nov.-Dec. 1976, 7 pages.
Ye et al, Formation of Monodisperse Polyacrylamide Particles by Radiation-Induced Dispersion Polymerization. I. Synthesis and Polymerization Kinetics, Journal of Applied Polymer Science, vol. 86, pp. 2567-2573, (2002).
Related Publications (1)
Number Date Country
20160282518 A1 Sep 2016 US
Provisional Applications (2)
Number Date Country
60695783 Jun 2005 US
60652809 Feb 2005 US
Divisions (2)
Number Date Country
Parent 14196006 Mar 2014 US
Child 15175526 US
Parent 12896930 Oct 2010 US
Child 14196006 US
Continuations (1)
Number Date Country
Parent 11351907 Feb 2006 US
Child 12896930 US